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Abstract
Development of a Novel Plasmid-based Gene Integration System for
Lactobacillus reuteri for the Persistent Treatment of Celiac Disease
Jeremy LaBarge
Celiac disease (CD) is an autoimmune disorder that affects approximately 1% of the pop-
ulation [55]. CD is characterized by intestinal villus atrophy after consumption of gluten from
wheat, barley, or rye. Patients with CD often experience abdominal pain, diarrhea, malnutri-
tion, fatigue, and a failure to thrive. There is currently no treatment for CD. Patients must
live on a strict lifelong exclusion of dietary gluten. Due to the high content of gluten in western
diets and poor labeling of gluten content, adherence to a gluten free diet (GFD) is difficult [15].
Nearly all the enzymes that can digest the gluten peptide are sensitive to the stomach’s low
pH . As a result, dietary supplementation with enzymes to digest gluten has yet to produce a
viable alternative treatment to a GFD.
We propose to use a resident microbe of the human intestinal tract to express a peptidase to
digest the immunoreactive gluten fragments. The bacteria, L. reuteri, will colonize the host’s
intestines and digest the gluten peptides before causing an autoimmune response. To accom-
plish this task, this thesis describes a food grade, plasmid based system to integrate genes into
the genome of L. reuteri. The plasmid system utilizes an origin of replication that requires a
protein, RepA, to propagate itself. A helper plasmid provides the RepA protein in trans to
an integration plasmid that cannot provide RepA to itself. The integration plasmid carries a
homologous region to the genome of L. reuteri allowing for targeted genomic integration. The
integration plasmid will not replicate on its own, and will be integrated into the genome if the
helper plasmid is absent. To select for these genomic integrants the integration plasmid ex-
presses an erythromycin resistance marker. Using the Cre/Lox system the antibiotic resistance
will be removed from the bacterial genome to re-establish the L. reuteri’s food grade status.
This thesis describes the construction and verification of the above mentioned plasmid tool kit
containing the helper, integration, and Cre expression plasmids to integrate genes into the L.
reuteri genome.
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1 Introduction
CD is often described as an “allergy to wheat”. This colloquial definition is misleading for a two
reasons. First, CD is an autoimmune disorder, similar to type I diabetes, not an allergic reaction.
Second, the disorder is triggered by the ingestion of gluten, which can come from barley, rye and
wheat. Thus, while wheat is the most common source of gluten, it is not the sole source of gluten.
Though convenient in describing CD to the lay person, “an allergy to wheat” is actually a poor
description of the true nature of CD.
1.1 Symptoms of Celiac Disease Pathology
Outward symptoms of CD vary among patients and can result in a wide spectrum of severities.
The disease most often manifests itself with intestinal problems resulting in diarrhea, weight loss,
and/or malnutrition [39]. Diarrhea is the main mode of presentation, found in 85% of individuals
with CD. Some patients have very severe intestinal problems, whereas other patients have mild to
no symptoms of the disease. Other, but less common symptoms of the disease include anemia and
osteoporosis. Patients with CD are also more prone to autoimmune disorders like type I diabetes
and other malignancies such as non-Hodgkin’s lymphoma, melanoma, and esophageal carcinomas
[27],[14]. Many absorption problems are a result of changes in the villus, the absorptive part of the
intestine, in the duodenum (the uppermost part of the intestine). Patients with active CD exhibit
highly reduced villi, or villus atrophy (Figure: 1 A and B), in their upper intestinal lining and have
reduced surface area to absorb nutrients. Furthermore, patients with celiac disease have increased
levels of lymphocytes and plasma cells in the lamina propria. Patients also exhibit increased levels
of cellular mitosis in the crypts (Figure: 1 C) of the villi, resulting in reduced crypt depth or crypt
hyperplasia [39].
The above mentioned symptoms and pathologies are only present when an individual with CD
consumes gluten from wheat, barley, or rye [39]. These three grass varieties have a common ancestral
origin and all express similar gluten proteins that are activators of CD (Figure: 2). Conversely,
gluten obtained from oats, which is more distantly related to the other grains, seldom causes CD
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Figure 1: Intestinal biopsies stained with hematoxylin-eosin. (A) Normal healthy patient with normal
villi architecture. Note the villus appendages extending into the intestinal lumen. (B) Patient with CD
exhibiting atrophy of the villi. Note the smoothing of the villi across the intestinal lining. In both images
the intestinal lumen is the top white space and the intestinal layers are on the bottom. (C) Stylized cross
section of healthy intestinal villus to show the location of the lamina propria and villus crypts. Figures
adapted from [58] [53].
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symptoms [39].
Figure 2: Brief phylogeny of grains common in western diets. Wheat, barley, and rye are all descendants
of the Triticeae. Conversely oats are more related to the Aveneae . The ancestral similarity of wheat, rye
and barley is thought to explain why their gluten proteins trigger CD and oats do not. Figure adapted
from [39].
Currently the treatment of CD consists of a strict adherence to a gluten free diet (GFD) for
the life of the patient. If the patient does remove gluten from his/her diet, many of the aliments
associated with CD reduce in severity or completely disappear. However, living under a gluten free
regime is exceedingly difficult due to the high amounts of gluten in western diets. Additionally, foods
that are labeled gluten free or foods that typically do not contain gluten are often contaminated
with trace amounts of gluten from the manufacturing facility [15] [32]. North America and Southern
European countries have established levels of 20 ppm gluten intake as safe for those with CD.
Northern Europe has set the threshold at 200 ppm gluten. Catassi et al. (2007), recommends
levels closer to 20ppm gluten to protect individuals with heightened sensitivities to gluten. The
safe consumption of oats by patients with CD has been debated in the scientific literature. Some
studies have shown the consumption of oats to be safe for people with CD [37], [36],[31]; however,
different studies have shown some individuals with CD to be sensitive to oat consumption [46].
Holm et al. (2006), conducted a long term study with children to determine if consuming oats
resulted CD symptomologies. Diets of children with CD were monitored to ensure a gluten free
diet. The children were then asked to consume approximately 50 g of oats per day along with other
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gluten free foods. Patients who strictly adhered to the gluten free diet, but include oats in their diet
did not exhibit symptoms (reduced villus height crypt depth ratio of and increase in intraepithelial
lymphocytes) of CD after 2 years of oat consumption. During the 2-year trial volunteers were given
a purified oat product that had been confirmed to be gluten free. A subset of the children involved
reported no symptoms after 5 yrs of consuming commercially available oat products. When the
patients consumed gluten symptoms of CD arose, indicating the children still had CD [32].
1.2 Prevalence of Celiac Disease
The exact reason for the triggering of CD is unknown. However, there is strong evidence that both
genetic and environmental factors affect the onset of CD. Approximately 1% of western populations
are thought to be currently affected by CD [55]. Studies have also shown that over the past two
decades, CD has increased in Finnish populations. Between 1978-80 CD was found in 1.05% of
the population; however by 2000-01 the number of individuals with CD had risen to 1.99% [45].
This statistic was determined by testing stored serum samples from 1978-80 for CD and comparing
the samples to fresh samples from 2000-01. Evidence suggests the nearly doubling of CD is due
to a true increase in disease prevalence, and not to increased detection of CD. Lohi et al. (2007)
completed blind tests on stored serium samples which resulted in the same CD diagnosis compared
to the sample’s original diagnosis, ensuring increased detection was not the cause of the observed
increase in CD prevalence.
1.2.1 Swedish Epidemic of Celiac Disease
In the late 1970’s through the 1980’s, Sweden had an increase in the number of children and infants
diagnosed with CD. The incidence of CD fluctuated so quickly that a change in the genetic profile of
the Swedish population could not explain the rapid fluctuation of CD incidence. The rapid change
in CD incidence allowed researchers to examine the environmental factors associated with CD [35].
As infants experienced the greatest change in CD, researchers were able to examine the affects of
early diet on the likelihood of developing CD.
In the 1980s the Swedish government recommended that new mothers not feed gluten to their
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children before 6 months of age. After 6 months, mothers were asked to introduce gluten into
their diets. Traditionally Swedish, mothers cease breastfeeding after 6 months, resulting in infants
experiencing high levels of dietary gluten without breast milk. Then in the mid 1990s the Swedish
government recommended that mothers breastfed for 4 months and then slowly introduce gluten
into the diets of infants. After that shift in policy, the rates of CD rapidly dropped. Introducing
the infants to gluten slowly while still breast feeding supports the infants’ ability to generate an
immunological tolerance to gluten. Data gathered from the Swedish CD epidemic has resulted in
the encouragement of mothers to prolong infant breastfeeding in hopes of preventing CD [56], [8],
[35].
1.2.2 Breast Feeding’s Effect on Celiac Disease
The findings from the Swedish epidemic lead to the hypothesis that the timing of initial gluten
intake affects a person’s chances of developing CD. Researchers have found if breast milk is given
in conjunction with initial gluten uptake the infant is 52% less likely to develop CD [5]. Four po-
tential mechanisms are hypothesized to explain why breastfeeding reduces the chance of developing
CD. 1) Breastfed children have less gluten in their diets than children who are not breastfed [5].
Reduced exposure to gluten decreases the risk of developing CD in infants. 2) Breast milk protects
the infant’s intestines from bacterial infections [5]. Breast milk contains lactoferrin, lysoszyme and
IgA antibodies to protect againtst microbial infections [51]. Intestinal infections result in increased
intestinal permeability which is an important step in generating CD [21]. 3) IgA antibodies from the
breast milk may clump or agglutinate gluten preventing uptake of the antibody complexes [5]. Ag-
glutinated gluten complexes would be excluded from passing through the intestinal barrier because
of their size. 4) Breast milk may suppress the activity of T-cells and prevent the overreaction of the
infant’s immune system [5], [51]. Recent research has shown breast milk to modulate an infant’s
intestinal physiology [26]. It is therefore possible that breast milk may assist in the generation of
gluten tolerance while the infant’s immune system and gastrointestinal systems are maturing.
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1.2.3 Gluten Toxicity
Gluten is storage protein composed of two components, gliadin and glutenin, in wheat, barley and
rye. Gluten is most associated with baked goods such as bread. In baked goods gluten imparts a
soft or elastic texture to the product. Gluten may also be used as a stabilizer in foods where gluten
is unexpected such as ice cream or ketchup. The gluten molecules of wheat, rye, barley, oats are
all rich in glutamine and proline residues. When the gluten is partially digested in the stomach the
resulting protein fragments are enzymatically modified by tissue transglutaminase (tTG). Human
tTG is a 76 kDA protein made of 686 amino acids. The primary functions of tTG are protein cross-
linking, cellular signaling, and the addition or removal of amines from amino acids [24]. Levels of
tTG rise after tissue damage because it cross-links proteins during tissue repair [75]. The glutamine
residues of gluten are converted to glutamic acid residues deamidation by tTG [52]. The change
in glutamine residues results in a more negatively charged oligopeptide which has shown greater
toxicity to individuals with CD [70]. The modified gluten fragments are more immunogenic because
their negative charge allows for a tighter interaction adhesion to the MHC II complexes on CD4+
cells. The modified gluten oligopeptide is able to strongly activate immune cells in the intestine.
Vader et al. (2002), examined the activity of tTG to determine why certain grains become toxic
when acted on by tTG. By analyzing synthetic polypeptides with different amino acid residue
combinations around the glutamine residue, a set of rules were established that could predict the
locations of the deaminating activity of tTG. Proline’s location was found to greatly affect the
targeting of tTG on the oligopeptide. If a proline residue was found immediately after a glutamine
or 3 residues following the glutamine, tTG did not deaminate the glutamine to a glutamic acid.
However, if a proline was 2 amino acid residues after the glutamine, tTG converted the glutamine
to a glutamic acid. Vader et al. (2002) used the specificity rules for to identify potential MHC
binding peptides after being acted on by tTG. The partially digested gluten molecules of wheat, rye,
and barley were all predicted as targets of tTG. Furthermore, their algorithms showed the gluten
molecules of oats did not serve as tTG targets. Vader et al. (2002) also proposed the activity of
pepsin, cleavage after phenylalanine, tyrosine, leucine, and isoleucine, promotes the production of
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tTG targets in gluten residues [73].
1.2.4 Mechanism of Celiac Disease Pathology
CD is a result of many different environmental and genetic factors. CD has a 10% prevalence among
first degree relatives and a 70% concordance with monozygotic twins indicating CD has a strong
genetic component [70]. The primary genetic factor associated with CD is related to the HLA II
locus. These genes are a subset of the major histocompatability complex (MHC) class II genes,
and are responsible for the presentation of foreign antigens to immune cells. Nearly all individuals
correctly diagnosed with CD carry the HLA alleles HLA-DQ2 or HLA-DQ8. The HLA-DQ2 allele
confers CD susceptibility in most cases (approximately 90-95%), and the HLA -DQ8 allele is found
in the remaining individuals affected by CD [39].
When gluten is consumed it is digested in the stomach. However, due to high levels of glutamine
and proline (>30% and >15% respectively) its 3D structure is resistant to much of the proteolytic
processes normally associated with gastric fluids. These partially digested peptides then travel into
the intestinal duodnum. For CD to manifest, these gluten peptide fragments must pass through
the intestinal barrier and enter the lamina propria. There are a number of proposed mechanisms
to explain how the peptide fragments pass through the gut barrier, two will be presented below.
One model proposes the creation of localized lesions in the gut lining by infections. These lesions
increase gut permeability and allow gluten fragments to enter the tissue. Gut lesions would also
increase immune cell activity near the lesion. These immune cells may then inadvertently generate
the cytokine environment thought to be necessary to generate an autoimmune disease. Furthermore,
tTG levels and activity would also be increased to repair the lesion increasing the chances of creating
an autoantigen [39]. The second model is based on the activity of the protein zonulin. Zonulin is a 47
kDa protein that has been found to reversibly loosen the tight junctions of the intestine. Zonulin
levels are higher in individuals with active CD compared to individuals without CD suggesting
the immune response may influence zonulin expression [21]. Immunogenic gluten peptieds may
readily pass the gut barrier in patients with active CD because of losened tight junctions in the
intestine. Though the precise mechanism used for gluten peptides to pass the intestinal boundary
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is unknown, it is widely accepted that these peptides do enter the lamina propria. Once through
the intestine, the gluten peptides encounter tTG and are enzymatically modified and become more
immmunogenic [52].
Autoantibodies are thought to be generated when a tTG/gliadin peptide complex binds to a rare
B-cell receptor specific to tTG (cell bound antibodies) and taken up. Upon cellular processing, the
tTG and gliadin peptides would be loaded onto MHCII complexes. These gliadin/tTG fragments
are then presented on the B-cell’s HLA-DQ2 complex. The modified tTG fragments of gliadin have
an extremely high affinity to the HLA-DQ2 MHCII protein complex. even capable of displacing
previously loaded proteins while in the endosome [77]. A T-cell with a T- cell receptor specific to
gliadin (which is thought to be common) must then interact with the presented gliadin fragment
on the HLA-DQ2 molecule and activate the B-cell [71]. The activated B-cell then produces an
autoantibody against tTG. The consumption of dietary gluten ensures the presence of tTG/gliadin
complexes in the intestine. These protein complexes will continue to activate B-cells as mentioned
above as long as gluten is a component of the person’s diet [71].
The role of auto-tTG antibodies in CD pathology is not clear. One hypothesis is the localized
increase in anti-tTG antibodies may result in the inhibition of tTG in the surrounding area. The
inhibited tTG would not be able to activate transforming growth factor-β (TGF-β) [6]. TGF-β is
involved in the differentiation of epithelial cells. Therefore, if TGF-β is not activated, because of
the loss of the tTG by the anti-tTG antibody, cell differentiation might be impeded resulting in
mucosal transformations [6].
The tissue damage observed due to CD is a result of the inflammatory response from surrounding
CD4+ T-cells. T-cell activation occurs when antigen presenting cells (APC) take up digested gluten
peptides (via phagocytosis) and presents the processed fragments on HLA-DQ2 or -DQ8 molecules.
A T-cell specific to the gliadin molecule, is then activated by interacting with the APC. The
activated CD4+ T-cell then secretes interferon γ which directs the immune system toward a cell
mediated response which mediates tissue damage [39] [6], [70]. Structural rearrangements of the
intestine occur through a number of poorly characterized steps that are known to be associated
with matrix metalloproteinases. The matrix metalloproteinases are able to destroy connective
8
tissues in the gut. The loss of the connective tissue via metalloproteinases results in changes of cell
proliferation and cellular migration. These two features result in the villus atrophy of the intestine
observed when a patient with CD has consumed gluten [70].
1.3 Treatment of Celiac Disease
There is no cure for CD. Knowledge of the molecular pathways involved with CD has opened new
avenues to treat CD. Blocking the activity of tTG, destroy gluten specific T-cells, and altering
the cytokine environment in the gut are all possible methods to treat CD [16]. However, the side
effects of targeting the previously mentioned elements of CD are thought to be too severe to be
considered for current treatments for CD. A strict, life long gluten free diet is the only currently
accepted treatment for CD. Investigators have suggested supplementation of prolyl endopeptidases,
to digest the gluten peptides before entering the duodenum, into the diets of individuals with CD
[66]. Many prolyl endopeptidases are inactivated in the low pH environments of stomach and are
sensitive to digestion with pepsin [72]. A prolyl endopeptidase found in Aspergillus niger was shown
to be resistant to gastric conditions, and may be suitable for dietary supplementation. However,
the peptidases are inactive in basic environment found in the intestines. If an enzyme could be
identified that survives the low pH of the stomach but is active in the intestines, it would need to be
taken before or with a meal much like lactose intolerant patients take lactase with dairy products.
Additionally if the peptidase was encased in a protective capsule the enzyme could survive passage
through the stomach [17]. Another alternative is to use bacteria in the gut to produce and secrete
enzymes to digest immunogenic gluten peptides as they leave the stomach. As a result the bacteria
would deliver a virtually unlimited source of the enzyme at the site of celiac pathology.
1.4 Probiotics
Though often overlooked, the microbial communities that inhabit the body serve important func-
tions. In fact, the intestine is the most densely populated microbial community in the human
body, and is thought to be where microbial communities exert their greatest effect on the host. For
example, using mice with intestines colonized with only Bacteroides thetaiotaomicron, researchers
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found the bacteria helps the host with digestion, absorption, metabolism of xenobiotic compounds,
angiogenesis, and the fortification of the intestinal barrier. No single definition for probiotics has
been accepted throughout the literature. However, the common link between proposed definitions
is: when probiotic microbes are introduced to the host they will confer some additional benefit to
the host or enhance a currently existing process in the host. It has also been found that probiotic
microbes help their host by crowding out potentially harmful bacteria. Mice that lacked microbes
in their intestines required a higher caloric intake than mice with microbial communities in their
intestines [34]. Due to the health benefits of the probiotic organisms, industry is introducing pro-
biotic bacterial strains into foods e.g. yogurt, cheese and ice-cream [54]. Common probiotic genera
of bacteria include Lactobacillus, Bifidobacterium, and Streptococcus.
1.4.1 Evidence or Probiotic Benefits
It has been estimated that roughly 300-400 cultivatable species from approximately 190 genera of
bacteria live inside the human intestinal tract. Furthermore, the predicted number of bacteria in
the intestines is 1014, which equates to 10 times as many bacterial cells as eukaryotic cells in the
entire human body [33]. Host organisms significantly benefit from the dietary supplementation of
probiotic bacterial strains. Probiotics are often administered to enhance or restore the normal gut
flora. When patients receive antibiotics, the antibiotic will often disrupt the microbial balance in the
intestines. As a result, some patients suffer from diarrhea after the cessation of antibiotic treatment.
The addition of probiotic strains to the diets of those who take antibiotics reduces the chances of
antibiotic associated diarrhea. Hickson (2007) found the probiotic strains Lactobacillus casei, L.
bulgaricus, and Streptococcus thermophilus reduced the chances of diarrhea when introduced into
the diet. Patients, previously on an antibiotic medication, who took a probiotic supplement were
∼20% less likely to show signs of diarrhea when compared to individuals given a similar sterilized
supplement [30].
Diarrhea in infants is a common cause of infant mortality. Infants are more prone to intestinal
diseases because their immune system and microbial gut flora have not fully developed [61]. Re-
searchers have proposed using probiotics to support the infants intestinal tract to defend against
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common pathogens like the rotavirus. Saavedra and Bauman (1994) found that adding Bifidobac-
terium bifidum and Streptococcus thermophilus to infant formula dropped the rates of rotavirus
diarrhea from 19% to 7%. Additionally, they found that the amount of rotavirus shed by the in-
fants taking the probiotic formula was reduced compared to infants who took the same formula
without the probitic strains. After two days 74% of children who took a probiotic supplementation
with Lactobacillus reuteri showed no signs of rotavirus associated diarrhea. Conversely, only 16%
of children showed no signs of diarrhea without the probiotic drink [64].
1.4.2 Previous Molecular Biology in Lactic Acid Bacteria
Probiotics are often common intestinal bacteria that show positive effects on human health. Some
researchers have proposed that the benefits of probiotics may be enhanced by modifying these
bacteria to perform specific targeted functions. One of the proposed functions of modified probiotic
lactic acid bacteria (LAB) is for the delivery of oral vaccines. Oral vaccines are important in large
scale vaccination programs because they can be administered to large populations without trained
personnel [50]. Different species of LAB (Streptococcus gordonii and Lactococcus lactis) have been
used to present antigens on their surface because of the inherent colonizing behavior of each strain.
S. gordonii is known to colonize the oral cavities of humans and only transiently pass through the
intestines. Conversely, L. lactis does not colonize the human intestinal tract and will be excreted
after consumption. Researchers have yet to determine if a persistent (due to colonization) or an
acute (due to transient exposure) dose of antigen generates a stronger intestinal mucosa immune
response. Mercenier et al. (2000) suggest that using different species of Lactobacillus may prove
the most fruitful in developing engineered probiotics. Lactobacillus is a diverse group of bacteria
that interacts with the human gut in many different ways. Some species do not colonize the gut
and could be used as transient delivery systems, whereas others colonize specific locations of the
gut and allow for directed applications of the probiotic.
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1.4.3 Delivery of Probiotics
For many applications a probiotic strain is only useful if it survives and multiplies in the intestinal
tract of the host. The bacterial strain must pass through the mouth, esophagus, stomach and pass
the bile ducts before it reaches the intestines. In the stomach, the bacteria are exposed to a low pH
environment and a myriad of peptidases. The bacteria must then resist the bile salts secreted by
the liver in the small intestine. Without food or another carrier molecule, bacteria often experience
a rapid die off after consumption [25]. To protect the bacteria from harmful digestive enzymes
and chemicals, probiotic strains are often given in conjunction with dairy products such as, cheese
[25], yogurt [63], and ice cream [29]. The diary products buffer stomach acids and raise the pH
of the stomach so the bacteria are able to survive. Furthermore, it is believed the and lipids
polysaccharides in the dairy products help the bacteria survive [25]. There are also a number
of technologically advanced methods of encapsulating the bacteria into microcapsules to protect
the bacteria. However, many of these methods reduce the viability of the bacteria by several-
fold. For review of some of the existing methods see [7]. Beyond using dairy products, a method
showing promise is the use of cellulose acetate phthalate (CAP) as a microencapsulating agent.
The solubility of CAP is dependent on the external pH of the environment. If the pH is below
6, CAP is not soluble. However, if the pH is greater or equal to 6, CAP becomes soluble. CAP
could be used to create protective capsules around the probiotic bacteria and shield the bacteria
from the acidic environment of the stomach. Then, when the bacteria pass into the intestine, and
the pH approaches 7, the microcapsules would dissolve and release the probiotic directly into the
intestinal lumen. Using CAP to protect Lactobacillus acidophilus has already shown promise [22].
When encased in a CAP microcapsule L. acidophilus was able to survive the acid environment of
the stomach with a single log unit loss of viability compared to a complete loss of viability when
not protected. L. acidophilus is normally quite tolerant to bile salts, so the study was not able to
assess if microencapsulation helped with bile tolerance. However, other methods of encapsulating
L. acidophilus have been known to sensitize the bacteria to bile, while CAP microencapsulation
did not sensitize L. acidophilus to bile.
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1.5 Goals of this Work
The goals of this project are to develop an engineered probiotic that will be an enduring treatment
for CD. We propose to engineer a common resident microbe of the human intestinal flora to digest
the gluten peptides before they can trigger damage the gut lining. The bacteria will be modified
to express a peptidase that digests the immunogenic fragments of gluten on its surface. We chose
to anchor the peptidase to the surface of the probiotic instead of secreting the peptidase because
the localization of the peptidase would maximize the effectiveness of the probiotic. If the peptidase
is secreted from the bacteria it will constantly be lost from the site of pathology. However, if we
anchor the peptidase to the surface of the bacteria, it can colonize the site of pathology and localize
the peptidase on the intestinal walls where CD pathology is observed The peptidase gene will be
integrated and expressed from the genome of the bacteria to ensure persistent gene expression. If
the peptidase were expressed from a plasmid, the plasmid would be lost to the environment without
constant antibiotic antibiotic selection.
The primary site of celiac pathology is the duodenum; therefore we sought a probiotic that
would colonize that area of the small intestine. Studies that track the gut microbial flora often
use fecal samples to detect bacteria. However, using fecal samples does not identify where the
bacteria originated in the intestine. The intestinal colonization site of L. reuteri. was verified
using fluorescence in situ hybridization [74]. Valeur et al. (2004) analyzed intestinal biopsies
from different intestinal locations from volunteers before and after a dietary regimen of L. reuteri.
Samples were then histologically prepared and probed for L. reuteri. L. reuteri was found localized
to the human stomach, duodenum and ileum [74]. Therefore, we expect L. reuteri will colonize to
the site of celiac pathology upon oral administration.
Furthermore, for the engineered probiotic to have commercial success it must be deemed safe
by the scientific and food communities. The Lactobacilli have maintained a generally recognized
as safe (GRAS) rating since 1997 [2]. The safety of L. reuteri has been further investigated among
patients who are immune compromised [76]. Wolf et al. (1998) found HIV+ individuals could
tolerate 1x1010 CFU per day of L. reuteri without harm.
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Initial administration of this study’s engineered probiotic will likely take place in dairy prod-
ucts, due to the lower cost and the availability of skilled personnel at Cal Poly’s Dairy Products
Technology Center. However, using microencapsulation technology might provide a more efficient
delivery system as the product moves toward industrial scales. Regardless of the delivery method, it
is important that enough probiotic bacteria are given to the host to allow proper colonization of the
probiotic strain. The standard amount of bacteria thought to be required for proper colonization
is between 107-108 viable cells/g or ml of product [25]. The delivery method used to deliver the
engineered probiotic should be judged based on its ability to deliver enough bacteria to successfully
colonize the host.
2 General Materials and Methods
2.1 Bacterial Strains and Media
The strains of Escherichia coli, Lactobacillus reuteri and Bacillus subtilis are described in Table 1.
E. coli and Bacillus subtilis was grown in, LB Miller media(FisherBrand). L. reuteri was grown in
MRS (Oxid). The media was autoclaved at 116 for 15 min at 121 psi to prevent caramelization.
Cultures of L. reuteri were grown at 37 in a candle jar to provide a low oxygen environment.
When transforming L. reuteri LCM [3] was used. When selecting for plasmids, the appropriate
antibiotics were used. For E. coli, ampicillin was used at 100 µg/ml, chloramphenicol at 20 µg/ml,
erythromycin at 250 µg/ml, and kanamycin 30 µg/ml. For L. reuteri chloramphenicol was used
at 8 µg/ml and erythromycin at 5 µg/ml. When using pGK12 or its derivatives, resistance to
chloramphenicol and/or erythromycin were induced in E. coli and L. reuteri using 500 ng/ml and
100 ng/ml respectively. Antibiotic resistance was induced for one hour in E. coli, and three hours
in L. reuteri.
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Table 1: Strains of bacteria used
Species Strain Genotype
E.coli dH5α T1R F’proA+B LacIq ∆(lacZY-argF)U169 recA1 endA1
HsDR17 (rk-,mk+)poA supE44 thi-1 GyrA96 tonA
(confers resistance to phage T1)
Turbo F’ proA+B+LacI1∆lacZ M15/fhuA2 ∆(lac-proAB)
glnV gal R(zgb-210 : : Tn10) TetS EndA1 thi-1
∆(hsdS-lue)7697)galU GalK rpsL(StrR) endA1 λ−
Top10F’ F’[lacIq Tn109(TetR)] mcrA ∆(mrr-hsdRMS-mcrBC
ϕ80LacZ∆M15 ∆lacX74 deoR nupG RecA1 araD
∆(ara-leu)7697 GalU GalK rpsl (StrR endA1 λ−
BL21 (DE3) F− ompT gal dcm lon hsdSB(rB−mB(rB−)λ(DE3
[LacI LacUV5-T7 gene 1 ind1 sam7 nin5])
EC101 JM101 E.coli Expressing RepA via plasmid integra-
tion. Select with Kan40µg/ml to keep the RepA inte-
grant. [42].
K12 Wild type strain
L. reuteri 100-23C
ATTCC 23272
B. subtilis 168
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2.2 Plasmid Isolation and Propagation
To isolate plasmids from E. coli, cells were grown overnight in LB supplemented with the necessary
antibiotics. Plasmids were isolated using the manufacturer’s protocol and supplies from the Zippy®
Plasmid Miniprep Kit from Zymo Research. To isolate plasmids with the ColE1 origin, 600 µl
of cells was harvested before using the Zippy® Plasmid Miniprep Kit. However, pGK12 and
its derivatives required 1.2 ml of cells. To isolate plasmids from L. reuteri, cells were grown under
antibiotic selection overnight in MRS. Approximately 2-3 ml of cells were harvested and resuspended
in 600 µl of sterile water. The cells were incubated for 30 min at 37 with 10 µl of 10 µg/ml
lysozyme and 5 µl of 10 KU/ml mutanolysin. The L. reuteri cells were then processed using the
Zippy® Miniprep Kit from Zymo Research using the manufacture’s protocol and supplies.
All of the built plasmids were generated and propagated in E. coli and then transformed into
L. reuteri.
2.3 Molecular Work
PCR was accomplished using one of two enzyme systems, Taq polymerase or Phusionpolymerase
(Finnzymes). With Taq PCR, the GoTaq® buffers (Promega) and enzymes were used. A typical
reaction contained: 1 µl template DNA, 0.2 muM each dNTP, 2 µM MgCl2 1X green GoTaq buffer,
0.5 µM forward primer 0.5 µM reverse primer 1 U GoTaq enzyme and nanopure water up to 25
µl final reaction volume. The following parameters were used to amplify the DNA: 95 - 2 min
followed by 25 cycles of 95 - 30 sec, 55 - 30 sec, 72 - 1.5 min with a final extension of 72
- 5 min. The extension time would change depending on the length of the amplicon(1 min/kb of
amplicon), and the annealing temperature was optimized for each primer set based upon Tm (∼2
below) (Table 2). A typical reaction for the phusion polymerase would consist of: 1 µl template
DNA, 1X HF buffer , 0.5µM each dNTP, 0.5 µM forward primer,, 0.5 µM reverse primer, 0.2 U
Phusion(Finnzyme) polymerase, and brought to 20 µl with nanopure water. The reaction would
then be run with the following parameters: 98 - 30 sec followed by 25 cycles of 98 - 10sec, 55
- 30 sec, 72 - 1 min, then final extension of 72 - 5 min. The block would be preheated to 98
16
to provide a hot start. Annealing temperatures were optimized for each primer set based upon Tm
(55 or 3 above) (Table 2). Extension times would vary and were adjusted to ∼15 sec/kb of
amplicon. For both Taq and Phusion reactions, the cycles could be increased depending on starting
amount of DNA and final amount of amplicon desired.
2.4 Restriction Digests
Restriction digests were preformed using NEB restriction enzymes and buffers. A typical reaction
would be run at 37 for 1-2 hrs. Digests were always done with less than 5% total volume
contributed from the enzyme to ensure low star activity. Heat inactivation of the enzymes was
accomplished using the recommendations from NEB, usually 65 to 80 for 20 min. Single
enzyme digests were done in 10 or 20 µl reactions, while double digests were always done in ≥20
µl reaction volumes.
2.5 Ligations and Digestion Independent Coning (DIC) Reactions
Ligations of plasmids was accomplished using NEB or Promega T4 ligase enzymes. The reaction
was done in NEB digestion buffers (preferably buffer 4) supplemented with 1mM ATP. Incubation
times and temperatures varied depending on the supplier of the enzyme and the nature of the cut
(sticky or blunt ends). Using an agarose gel image to estimate molar ratios of insert and vector,
approximately 3:1 insert to vector molecules were added to the ligation mixture. When ligating
inserts with the same cut site on either end, the vector backbone was treated with NEB Antarctic
Phosphatase following manufactures recommendations and heat inactivated at 65 before ligations.
Restriction enzymes were heat inactivated before treating the vector with a phosphatase. If heat
inactivation was not possible, the reaction was either column cleaned with the Zippy® Column
Clean Kit or the Zippy® Gel Purification Kit. Orientation of inserts were determined using colony
PCR with Taq polymerase enzymes.
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DIC reactions were accomplished by first amplifying the insert and vector with Phusionpol-
ymerase. The amplified products were purified away from primers in the previous reaction with
either Zippy spin columns or gel purification. The amplicons were run out on an agarose gel to
estimate relative molar ratios. An approximate 3:1 insert to vector molar ratio was added to each
DIC reaction. The DIC reaction contained as follows: X µl vector DNA, Y µl insert DNA, 1X HF
buffer, 0.2µM each dNTP, 0.2U Phusionpolymerase, and fill to 20µl with nanopure water. The
reaction was then run at: 98-30 sec. followed by 10 cycles of 98 - 10 sec, 55 - 30 sec, 72 -
2 min, then a final extension of 72 - 5 min. The annealing temperature was determined by the
amount of homology between the insert and vector (Table 2). For details on the DIC procedures
see [65]
2.6 Transformation
Transformation of E. coli was accomplished using chemically competent cells. Cells were prepared
using the Z-competent® E. coli transformation kit from Zymo Research. Following the manufac-
turers protocol and aliquoted into 100 µl aliquots. Cells were used immediately or frozen at -80
(snap freezing with liquid nitrogen was found unnecessary). If frozen, the cells were thawed on ice
for 5-10 min or until completely thawed. Sample plasmid or ligation DNA (no greater than 5%
total volume of cells) was added to 50 µl of chemically competent cells. The cells were incubated
on ice for approximately 10 min and transferred to a 42 heat block for 30 seconds, followed by an
immediate quenching on ice for ∼5 min. Cells were removed from ice and 250 µl of SOC was added
and immediately placed at 37 with shaking (∼220 rpm) for 15 min. If the cells were selected with
ampicillin, they were plated after the 15 min outgrowth period. If selected with chloramphenicol,
erythromycin, or kanamycin, the cells were given 1 hr before plating. Furthermore, if pGK12 or its
derivatives were used, resistance was induced using lower concentrations of antibiotic (see bacterial
strains and media) for 1 hr. Once the liquid had soaked into the media, the beads were removed and
the plates incubated at 37 overnight or until growth was observed. Often cultures selected with
chloramphenicol or erythromycin took ∼48 hrs to grow. To transform L. reuteri, electroporation
was used with a modified protocol from Ahrn et al. (1992). An overnight culture of L. reuteri was
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grown in LCM [3] at 37 with low oxygen. Fresh LCM (10 ml) was then inoculated 1/100 from the
overnight and allowed to grow an OD600= 0.6-0.8. Cells were harvested by centrifugation (4,000 Xg
for 5 min at 4) and washed twice with equal volumes of sterile ice cold water. After the second
wash, the cell pellet was resuspended in 1/10 the original volume with EHR buffer (1mM HEPES
0.5M Raffinose, pH 7.0) [3]. Cells were then centrifuged as before and resuspended in 1/100 original
volume EHR buffer. L. reuteri cells were the aliquoted (100 µl) into ice cold 1.5 ml tubes. About 1
µg (5 µl) of circular plasmid DNA was then added to the cells and allowed to incubate for 10 min on
ice. To each electrocuvette (0.2 cm gap), 80 µl of cells was added and single pulse of 2.5 kV at 246
Ω was applied. The plus lengths were ∼10 ms. Immediately folowing electrophoration cells were
then in 1 ml of pre-warmed (37) LCM broth supplemented with induction levels of erythromycin
or chloramphenicol (see bacterial strains and media and Table 3) and incubated at 37 for 2 hrs.
50 µl of cells was spread on a half plate of LCM with full antibiotic selection. The remaining cells
were added to 4 ml LCM with full antibiotic selection (Table 3) and allowed to grow at 37 in a
candle jar for 24-48 hrs or until colonies were visible. Electrocompetent L. reuteri cells can also
be frozen for later use by resusping them in a 1/100 volume of water after the second wash and
freezing at -80. Aliquots were then thawed and washed in 1 ml water followed by a wash in 1 ml
EHR. Cells were then centrifuged as above and resuspended in 100 µl EHR and electroporated as
above.
2.7 Plasmid Construction
The construction of each plasmid will be discussed separately in future chapters of the thesis.
Table 3: Plasmids used in this study
Name Plasmid Description Resistance Markers
JL101 pGK12 ErmC ORF removed LacIPZ ligated with
EcoRI in same orientation as ErmC ORF
Cm†
JL102 pGK12 ErmC ORF removed lacIPZ ligated with
EcoRI in the opposite orientation as the ErmC ORF
Cm†
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JL103 pGK12 ErmC ORF removed and self ligated with
EcoRI
Cm†
JL106 PLST from SlpA blunt cloned into pCR4 sequencing
vector in the sense orientation
Amp, Kan
JL108 JL106 with LacA(from L. reuteri clone in using SpeI Amp, Kan
JL110 JL108 with the pGK12 origin and ErmC inserted
with PstI
Amp, Erm‡,Kan
JL111 JL110 with CpC Gus Ligated in with EcoRI Amp, Erm‡,Kan
JL114 GFP from pET30 GFP is replaced with GusA ( via)
AscI
Kan
JL115 ClpP-GFP-His ligated into EcoRI sites of pGK-PLT Erm‡
JL116 ClpP-Gus-His ligated into EcoRI sites of pGK-PLT Erm‡
JL117 pCR2.1 with Clp-CtsR TA cloned in sense orienta-
tion
Amp, Kan
JL119∗ Gus-His integration plasmid containing LacA (from
L. reuteri) and pGK12 origin and ErmC gene
Erm‡
JL120∗ GFP-His integration plasmid containing LacA (from
L. reuteri) and pGK12 origin and ErmC gene
Erm‡
JL121 pGK derivative with Cre ORF (from PMB145) fused
to first 78 aas of ErmC gene
Cm†
†: Chloramphenicol must be induced with 250 ng/ml chloramphenicol for before adding 20
µg/ml chloramphenicol.
‡: Erythromycin must be induced with 100 ng/ml erythromycin before adding 250 µg/ml
erythromycin.
*: Plasmids must be propagated in EC101.
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3 Creating ClpP Expression System to Drive Peptidase Expression
3.1 Previous Peptidase Promoter Systems
Initial work to develop an expression system for our peptidase was done by Matthew Shurtleff.
The criteria for the expression system is constitutive high expression of the peptidase. Using the
criteria, the promoter elements of the gene SlpA from Lactobacillus acidophilus was chosen, as
SlpA is constitutively expressed at high levels (about 10 percent of the overall cellular protein)
[10]. Furthermore, the S-layer protein is actively excreted outside of the bacterial cell and anchored
so that is creates a matrix around the bacterial cell [68]. Due to the large numbers of S-proteins
found on cellular surfaces, researchers have estimated that an average of approximately 500 S-layer
proteins must be synthesized, translocated and anchored every second [68]. With the previous
criteria satisfied, Shurtleff replaced the Slp-A gene, leaving the leader and anchor sequences, with
different peptidases or GFP. In doing this, he retained the use of the Slp-A promoter, Shine-
Dalgarno sequence, leader sequence , anchor sequence, and transcriptional terminator. The cloning
of these constructs into E. coli was exceedingly difficult. Restriction digests of isolated plasmid
constructs with the Slp-A expression system displayed unexpected banding patterns, indicating the
plasmid possessed deletions in the open reading frame (ORF) after the SlpA promoter. Shurtleff
learned the anchor sequence of the Slp-A gene had been shown to have murein hydrolase activity
[1]. This discovery led him to believe the anchor’s enzymatic activity was digesting the cell wall of
E. coli. The problem was further exacerbated because the cell wall anchor sequence was targeted
to the periplasmic space of E. coli. To alleviate the problem, Shurtleff truncated the C terminus
of the anchor sequence. Previous studies have shown that C terminal end of the Slp-A protein was
sufficient to anchor proteins into the cell wall of lactic acid bacteria [69]. With the truncated anchor,
he was able to build plasmid constructs with GFP and different peptidase cassettes using the Slp-A
genetic elements. However, these plasmids were unstable, leading to the belief the plasmids may still
be toxic to E. coli. To determine the source of the toxicity, Shurtleff cloned different combinations of
the Slp-A genetic elements into the pET30 vector. The pET30 vector is a commonly used expression
system that has tightly controlled regulation of gene expression. The pET30 plasmid uses IPTG to
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induce expression of proteins cloned into the plasmid. In these expression experiments, he discovered
that when the Slp-A leader and anchor are expressed alone they are highly toxic to E. coli. If a
peptidase was inserted between the leader and anchor sequences of Slp-A, toxicity to the cells was
not observed, however the recombinant protein was found in inclusion bodies. Two hypotheses
were proposed to explain the loss of toxicity: 1) the inclusion bodies were no longer capable of
exerting the toxic effect, or 2) the addition of the peptidase may cause a conformational change in
the Slp-A leader sequence or the truncated anchor sequence which negates the toxicity. For a more
complete explanation of the Slp-A gene structure and the difficulties in protein expression using
Slp-A genetic elements, see the Masters Thesis of Matthew Shurtleff [65].
3.2 New Potential Promoters for Peptidase Expression
To alleviate the toxicity problems when using the SlpA promoter elements, a different expression
system was chosen. The elements of Slp-A that were suspected to be toxic were the promoter,
the anchor, or the leader. Therefore, we decided that for our proof of principle we would use
an inducible promoter. Furthermore, the new expression system would not target the expression
cassette to the cell surface. Without protein targeting and anchoring sequences, we could mitigate
the toxicity potentially imposed upon E. coli during the construction of the integration cassettes.
Furthermore, it was possible the Slp-A promoter strength was toxic to E. coli. The Slp-A promoter
may have resulted in the overproduction of its cassette which could overwhelm the protein chaperons
or deplete cellular resources. For our new expression system, we sought high expression in L. reuteri
with minimal expression in E. coli to eliminate the toxicity during plasmid construction.
Although gene transcription is well understood in Gram-negative bacteria such as E. coli, there
has been limited research on gene transcription in Gram positive bacteria [49]. Many inducible
systems require multiple genetic elements that are optimized for use in E. coli, but may not work
in L. reuteri. Therefore if we were to use an inducible promoter we would need a system that has
been shown to work in Gram positive bacteria. An approach used to obtain constitutive Lacto-
bacillus promoters is creating synthetic promoter libraries [59]. To generate the new promoters,
Rud et al. (2006) modified known ribosomal RNA promoters. By aligning known rRNA promoters
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consensus with known elements such as the -10 and -35 sequences, different strength promoters
were developed. Rud et al. (2006) used PCR primers containing a random mixture of nucleotides
to change the spacing between known sequences. These new promoters were then used to drive a
reporter gene (GusA). By randomizing the nucleotides between the known DNA sequences, pro-
moters were generated with strengths which varied ∼3-4 log units [59]. While the generation of a
customized promoters may be a valuable tool in optimizing the expression of our peptidase cassette
in L. reuteri, we chose to seek a known promoter system. Screening through different synthetic
promoters would divert us from generating the gene integration system in a timely manner.
3.3 Clp Promoter Expression
Instead of generating new promoters to drive peptiase expression, we chose to use a previously
described promoter clpC. In McCracken et.al. (2000) P-clpC was compared to the P-slpA along
with a number of different promoters in a variety of species of lactic acid bacteria. In the study the
group Lactobacillus fermentum, a close relative to L. reuteri [23]. P-clpC drove strong expression
of the reporter gene, GusA, but at lower levels than reported for P-slpA. With this information in
hand, we looked into the Clp family of promoters for a potential promoter we could use to drive
expression of our reporter protein.
The Clp family of proteins is involved in mitigating environmental stress, particularly heat
stress. The regulation of heat stress in Gram(+) and Gram (-) bacteria is quite different. In the
Gram(-) bacteria, heat stress is tolerated by the switching to a set of heat shock proteins. In E.
coli, a temperature shift from 30 to 42 results in a dramatic increase in the levels of σ32 to
activate over 20 genes related to heat stress [12]. These genes include a number of chaperones and
proteases that help refold or destroy misfolded proteins. The shift to higher levels of σ32 production
is controlled at the translational level. Through a change in the σ32 mRNA secondary structure
resulting in higher levels of translation [12]. With Gram(+) cells the heat shock response is more
complex. There are ∼200 genes that are induced that fall into six general classes of proteins.
Though the specifics of these classes are not important for this thesis, the combined effect is to
increase the amounts of chaperones and proteases during stressful episodes. The P-clpP natively
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drives the expression of proteins classified as class III stress proteins. These class III stress proteins
have play a roll
3.4 Reporter Genes
Before expressing the peptidase with ClpP we expressed benign reporter genes to ensure the integra-
tion system worked. One of the reporter genes we have chose to use is the protein β-glucuronidase
(GusA). A common reporter in E. coli is β-galactosidase. We felt β-galactosidase would not work
in our system because L. reuteri has β-galactosidase activity. Therefore, it would be difficult to
determine if the β-galactosidase activity was from our reporter or if it was background activity
from the native β-galactosidase expressed in the genome. GusA activity has not been shown in L.
reuteri. Therefore, detected GusA activity would be attributed to our expression system.
β-glucuronidase (GusA or uidA) is a 603 aas acid hydrolase, found in many organisms including
in E. coli and is known to cleave a variety of β-glucuronides. It has been widely used in plants [4]
and microorganisms [59], [49], [57]. The GusA reporter systems had many different substrates that
allow for enzymatic activity detection of using chromogenic substrates. This study used X-Gluc
and PNP-Gluc which are analogues to X-Gal and ONPG to the β–galactosidase substrates that are
commonly used when attempting α-complementation. When X-gluc is cleaved by GusA, it forms a
blue precipitate on agar plates. This allows for rapid screening of the bacterial clones which contain
GusA activity. When PNP-Gluc is cleaved by GusA, it forms a yellow soluble compound that can
be detected using spectrophotometric techniques. Therefore, the enzymatic units of the cells can
be determined with simple chromogenic assay procedures.
We also wanted an immediate assay that could be checked in vivo. We chose to use green
fluorescent protein (GFP) as a secondary reporter protein. GFP offers a number of benefits that
complement the GusA reporter system. Cellular clones with GFP can be quickly screened by
detecting visible fluorescence when exposed to long or short wave ultraviolet light (UV). If necessary,
there are also antibodies against GFP that can quantify the amount of GFP in the cell. Using these
two systems (GusA and GFP) we can generate both a readily detectable qualitative measure with
GFP, and a simple procedure for quantitative measurements using the chromogenic assay for GusA.
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3.5 Methods to Create Expression Cassette
3.5.1 Building ClpP and CtsR
Genomic DNA was harvested using the ZR Fungal/Bacterial DNA Kit(Zymo Research). To
amplify Clp-P, primers PClp-DicF and PClp-R (Table 2) were used to amplify a 106 bp fragment
from the B. subtilis genome. These primers were based off primers TM-197 and TM-187 from Derr
et al. (1999). The 5’ end of the P-Clp-P amplicon contains a homologous region to the pGK-MCS
plasmid and an EcoRI cut site. CtsR was amplified using the primers CtsR-DIC-F and CtsR-R to
generate a 659 bp fragment. The CtsR primers were based off the primers ID-1 and ID-2, also from
Derr et al. (1999). The non conventional start codon (GTG) of CtsR was replaced with an ATG
[19]. Furthermore, the distance from the Shine-Dalgarno sequence to the start codon was increased
to 8 nt from 6 nt in the hopes of increasing the translational efficiency of the CtsR transcript. The
CtsR transcript would be made as a polycistronic mRNA, therefore a 167 bp was added between
the GusA gene and the CtsR protein to act as a spacer for the two open reading frames.
3.5.2 Building GusA constructs
The GusA gene was amplified using the primers Gus-DIC-F and Gus-DIC-R to amplify the protein
DNA sequence. AscI sites were engineered before the start codon and before the stop codon of GusA.
Therefore, GusA could be interchanged with restriction enzymatic cleavage with other peptidase
ORFs. To generate the functional expression system, the P-Clp-P, CtsR and GusA amplicons were
column purified using the DNA Clean and Concentrator Kit(Zymo Research) and diluted 100 fold.
These amplicons were then added to a single PCR reaction containing the pClp-DicF and Gus-DIC-
R primers. The resulting amplicon was 2,573 bp long. To add the Slp-A terminator to the P-Clp-P
expression system, an existing plasmid pGK (MCS)PGT [65] was utilized. (The ‘T’ of PGT is
the SlpA terminator.) The primers Term-F and pGK5pMCS-R were used to amplify the plasmid
backbone (4617 bp in length) where the expression cassette would be inserted. P-ClpP-CstR-GusA
(amplified with PClp-DicF and Gus-DicR) was then switched into the pGK plasmid backbone via
DIC. This plasmid was then transformed into chemically competent E. coli (Turbo (NEB) or dH5α-
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T1R (Invitrogen) cells), and cells were then screened for positive transformants using colony PCR
with M13R and CtsR-R primers to generate an amplicon of 802 nt. The completed expression
cassette containing the Clp promoter, CtsR repressor protein and SlpA transcriptional terminator
will be called CpC from this point forward. The cassette between the AscI sites will be after
the CpC designation, the aforementioned sequence would be called CpC-GusA. The CpC-GusA
fragment was then cloned into the commercial vector pCR4 (Invitrogen) containing LacA gene
fragment and ErmC-pGKori sequence (discussed in more detail in the integration vector section
4.1.2 ).
3.5.3 Addition of His-Tag to Clp and CpC cassettes
The histidine(His) tag for each cassette was derived from the pET30 vector (Invitrogen). The
pET30 plasmid has both C- and N-terminal His tags engineered into the plasmid vector. The lab
has a pET30-GFP plasmid built with AscI sites flanking the ORF of GFP which is in frame with the
C terminal His-Tag of the plasmid. For the construction of pET30-GFP see [65]. GusA was inserted
into pET30 by replacing the GFP coding region with GusA at the AscI sites. Transformants were
screened for clones with GusA in frame with the His-tag using the primers Gus-DIC-F and the
pET30 T7-terminator (Invitrogen) for an amplicon of 1952 nt. To insert Gus-His or GFP-His into a
pGK-CpC Gus primers were developed to amplify the vector so we could include or remove the CtsR
repressor (Figure 4). Primers were also developed to amplify the cassette out of pET30 and retain
the His-tag. To create pGK-CpC-GusA-His, pGK-CpC-GusA was amplified using the primers pGK-
CpC-R and pGK-CpC-F to yield an amplicon of 5342 bp. Gus-His or GFP-His were amplified from
their respective pET30 plasmids using pET Nde-F and pET-His-top-R, which generated a band at
1923 bp for GusA and 828 bp for GFP. DIC was used to stitch either GusA or GFP into the pGK
CpC backbone. To remove CtsR, the primer set pGK-CpC-F and pGK-Clp-NoCtsR-R were used
to generate an amplicon at 4710 bp. This plasmid backbone would then be combined with GusA
or GFP using DIC as with the CPC inserts. When the CtsR gene was removed from the expression
system, the designation changed from CpC to Clp.
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Figure 3: Construction of the CPC expression cassette. Primer numbers refer to primers from Table 2.
For more details see materials and methods for expression cassette construction.
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Figure 4: Construction of pGk-Gus-His plasmid (JL116). To keep the CtsR repressor protein, use primer
6 in place of primer 5. Primer numbers refer to primers from Table 2. For more details see materials and
methods in the expression cassette construction section. To generate create JL115, use the same primers
as shown above but use pET30 GFP instead of JL114.
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3.5.4 Building pCR2.1 Clp-CtsR
Clp-CtsR was amplified with Taq polymerase from pGK-CpC-Gus using CtsR and PClp-Dic-F
for an amplicon 738 bp long. The amplicon was then ligated into pCR2.1 using the original
T/A Cloning Kit (Invitrogen) following manufactures instructions and cloned into TURBO E.
coli (NEB). Colonies were screened using colony PCR using M13R and CtsR-R for an amplicon of
870 bp. The resulting plasmid was names JL117 or pCR 2.1 Clp-CtsR.
3.5.5 GusA Assay
The Gus assay is a modified protocol from [57]. Cultures were grown to an OD600 between 0.4 and
0.8 and put on ice for 5 min. Cells were pelleted by centrifugation (16,000 Xg, 2 min.), resuspended
in Gus buffer (50 mM NaHPO4(pH 7), 10 mM β-mercaptoethanol, 1 mM EDTA, 0.1 % Triton
X-100), and lysed by 3 rounds of sonication for 20 seconds (intensity level 6 on the Fisher Scientific
ultra-sonicator). Lysates were centrifuged for 5 min at 16000 Xg max speed to pellet cell debris.
50 µl of cell lysate was then added to 0.5 ml of Gus assay buffer supplimented with 1.5 µM p-
Nitrophenyl-β-D-galactopyranoside (pNPG)(Acros Organics). The sample was then incubated at
37 until yellowing was observed or 30 min had passed. To stop the reaction, 100 µl of the sample
was removed and added to 0.8 ml 2 mM carbonate buffer(pH2). Read the sample at 405 nm. The
extinction coefficient used to calculate the PnP− was 18,700M−1 at 405 nm [67].
3.6 Results and Discussion for Expression Cassette
Our goal was to create an expression system that would drive the expression of our reporter genes
(GusA and GFP). We were able to properly stitch together the bacterial components as shown in
Figure 3. We had initially hoped that our new reporter system would not be active in E. coli,
yet be active in L. reuteri. However, we saw strong activity of the promoter in E. coli harboring
pGK-clp-Gus or pGK-clp-GFP (Figures 5 and 6). Reduced Gus activity observed in the presence
of the CtsR protein (middle column compared to right column in Figure 5) lead us to believe the
CtsR protein inhibits much of the Clp-P activity in E. coli. However, it does not completely inhibit
34
Figure 5: Activity of GusA in E.coli. Assays were done in a TURBO E. coli strain background. Enzymatic
units of GusA were defined as µM pNP−/min. No statistical significance could be applied to these samples
because too few replicates.
the Clp-P promoter’s activity. Therefore, if future peptidase cassettes are toxic in E. coli, the Clp-P
promoter system may not be suitable. When building the CpC cassette (Clp-P-CtsR-GusA/GFP)
there were concerns that the ∼150 nt spacer between the CtsR protein and the expression cassette
might contain a transcriptional terminator sequence. In Figure 5, the cells that contain pGK-
CpC-GUS show higher GusA activity (∼6X) than cells without the pGK plasmid. This piece of
evidence supports increased levels of GusA as a result of the plasmid’s gene expression. When the
CtsR protein is removed from the CpC cassette (pGK-clp-Gus), there is a dramatic increase in
the levels of Gus activity. The pGK Clp-Gus construct shows ∼141X and ∼812X more activity
when compared to pGK CpC-Gus and WT strains of E.coli (Figure 5). The reduced Gus activity
observed in the presence of the CtsR protein (middle column compared to right column in Figure
5) lead us to believe the CtsR protein effectively inhibits much of the Clp-P activity. However, it
does not completely inhibit the promoters activity.
GFP expression under Clp-P was also monitored (Figure 6). Strong fluorescence was seen in
cells containing pGK-clp-GFP. However, there was background fluorescence observed in E. coli
with pGK-clp-Gus. The fluorescence is so much brighter with pGK-Clp-GFP that we are confident
the fluorescence seen is due to GFP expressed by our plasmid, and not background fluorescence.
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Approximately a third of the cells show GFP fluorescence. Previous experiments have shown
plasmids with the pGK12 origin of replication to be highly unstable in E. coli (data not shown).
Shorty after the removal of antibiotic selection pGK plasmids are lost from the E. coli population.
Therefore, the plasmid instability may generates a population of cells with or without the pGK-
clp-GFP plasmid, and explain the low proportion of fluorescing cells.
We also co-transformed the pCR2.1 containing the clp-CtsR cassette into cells containing pGK-
clp-GFP (right most panel). We hypothesized we could express CtsR on a secondary plasmid and
have the CtsR protein inhibit the Clp-promoter on our expression plasmid (in this case pGK-clp-
GFP). The far right panel in figure 6 shows highly reduced fluorescence when compared to pGK-
clp-GFP (middle right panel). The reduced levels of fluorescence indicate CstR may be working
in trans on the expression plasmid and may reduce its promoter activity. It is possible we could
express cassettes that are toxic in E. coli if the expression is truncated by providing CtsR in trans.
4 Plasmid Based Integration System
If the peptidase used to digest gluten was expressed from a plasmid the plasmid would be lost
shortly after antibiotic selection was removed from the bacteria. As a result, patients using the
probiotic would need to be on an antibiotic regime for the probiotic to persistently express the
peptidase. Additionally, FDA regulations do not grant food grade status to products which can
introduce antibiotic resistance to the environment. Therefore our probiotic must stably express the
peptidase without antibiotic selection. To accomplish this goal the peptidase must be expressed
from the genome of L. reuteri and not a plasmid. Integration into the genome occurs when a
bacterial cell takes up a foreign DNA and incorporates the DNA into its genome. For these two
events to happen in L. reuteri DNA has to pass through the thick cell wall, and then recombine
with the bacterial gDNA. Integration of genes into bacteria has been accomplished by [38] one-step
genomic integrations [44] followed by screening. In general screens require a readily observable
product and many man hours to produce positive genomic integrants integrants. L. reuterihas a
low transformation frequency which further decreases the likelihood of obtaining positive genomic
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integrants. Therefore, the one step integration system does not provide a feasible method for
genomic integration. Another method used to integrate genes into the genome of Gram positive
bacteria uses two plasmids that are dependent on each other for proper replication[60].
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Our system will be based off the plasmid pGK12, [40] which harbors two inducible antibiotic
markers: chloramphenicol acetyl transferase (CAT) and erythromycin resistance marker C (ErmC)
[20]. The pGK12 plasmid is able to replicate in a wide host range including both Gram positive
and negative bacteria such as,L. reuteri and E. coli. The origin of replication in pGK12 is from
the plasmid pWV01 [62], [43]. For pGK12 to replicate, the RepA, protein must be expressed to
bind to the origin of replication on the plasmid. If RepA is not present, plasmids with the pWV01
origin will not replicate inside a cell. Our system takes advantage of the RepA dependence by
providing RepA in trans: a helper plasmid will express RepA while a second plasmid, the integration
plasmid, will have the RepA dependent origin of replication, but will not express the RepA protein.
Therefore, the integration plasmid will not propagate itself unless the helper plasmid supplies
the RepA protein (Figure 7A). Built within the integration plasmid will be a genomic integration
targeting region (LacA), the expression cassette (peptidase), and a selectable marker (ErmC). Using
this system, we increase our chances of a genomic integration by selecting for the presence of both
plasmids to generate a population of cells that contain both the helper and integration plasmids.
Genomic integration will then be promoted by removing antibiotic selection for the helper plasmid
(chloramphenicol) and destabilizing RepA with thermal stress [60] (Figure 7B). If RepA is absent,
the integration vector will no longer be able to replicate. Therefore the integration plasmid faces
one of two outcomes 1) integrate itself into the host’s genome via homologous recombination or
2) be lost by the cells during cell division. The first option can be favored by continuing selection
for the antibiotic marker on the integration vector (erythromycin). Therefore cells that do not
integrate the plasmid will lose their antibiotic resistance and will be selected against.
4.1 Methods for Helper and Integration plasmids
4.1.1 Methods for Building Helper Plasmid
Erm-Del-R and Erm-Del-F2 primers were used to amplify the vector backbone from pGK12, the
amplicon was 3732 bp. LacIPZ (1-92 aas of the LacZ /alpha fragment) was then amplified from
the gDNA of E. coli K12 using LacIPZ-F2 and PLacIPZ-R, yielding an amplicon of 1584 bp.
39
Figure 7: Dual plasmid integration schematic. (A) The helper plasmid provides RepA to both the
integration plasmid in trans. By selecting with different antibiotics, both plasmids are maintained in the
cells to generate a population cells with both plasmids. (B)Using thermal stress and removing the antibiotic
used to select the helper plasmid genomic, integrants are selected for.
These two products were then digested with EcoRI and the pGK12 vector amplicon was treated
with Antarctic phosphatase (NEB). The two fragments were ligated together and transformed into
chemically competent E. coli dH5α or TURBO. Blue transformants were screened for the orientation
of the LacIPZ insert using colony PCR. Colonies that were white were screened and verified to be
pGK12 without the erythromycin marker.
4.1.2 Methods for Building the Integration Plasmids
To act as a place holder for the blunt cloning site of the pCR4 vector. the SlpA expression vector
developed by Matthew Shurtluff was used. Primer sequences are defined in [65]. Briefly, Pro-Dic-F
and ProL-R were used to amplify up the Slp-A promoter and leader(PL) with an expected size of
375 bp. The SacI anchor sequence was amplified using A-TermF and Sac-1-term-R for a 165 bp
amplicon. The SlpA terminator region was amplified using Term-Dic-F and A-Term-Dic-R with an
expected size of 135 bp. The SacI anchor(S) and the terminator(T) regions were then gel purified
and stitched together using DIC to create ‘ST’. To combine ‘PL’ and ‘ST’, they were both digested
using AscI and ligated together. The ligation product was amplified by PCR using the primers
Pro-Dic-F and A-Term-Dic-R. This amplicon was TOPO cloned into pCR4 blunt sequence vector
using the manufactures protocol and transformed into Turbo E. coli cells (Invitrogen). The colonies
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were screened using colony PCR to determine the orientation of the PLST insert. Pro-Dic-F and
M13R were used for an amplicon of ∼800 bp in the sense orientation to create JL106 (Figure 10).
LacA was amplified from L. reuteri (23272) gDNA, obtained using the ZR Fungal/Bacterial
DNA kit(Zymo Research), using the primers LacSpe1-F and LacA-Int-R for a band that is 981 bp
in size. The LacA amplicon was inserted into pCR4 by digesting the plasmid and LacA amplicon
with SpeI, and ligating the two pieces together. To screen for for the correct orientation of the
LacA insert, colony PCR was used with the primers LacSpe1F and M13R for a band of 1036 bp
in size to create JL108. The origin of replication and ErmC (Erm-Ori) marker was amplified from
pGK12 using the primers Lox66-Ori-F2 and Lox71-Erm-R to yield a band 2,053 bp in size. This
amplicon along with PCR4-LacA-PLST(JL108) was digested with PstI. The vector was then treated
with Antarctic Phosphatase(NEB), and the two fragments were ligated together. The ligation
was transformed into E. coli (TURBO). The orientation of the ErmC-Ori insert was determined
using colony PCR and the primers M13R and Lox71-Erm-R to yield a band 2,109 bp in size to
create JL110. Once the pCR4 plasmid contained both LacA, the ErmC marker, and the Origin of
replication, it was designated pCR4 LAEO or JL110. To insert CpC GusA into JL110, pGK-CpC-
GusA and JL110 were digested with EcoRI, gel purified using the Zymo Research Gel Purification
kitand ligated together. The ligation was transformed into E. coli (TURBO), and orientation was
determined using Gus-Dic-F and T7 for an amplicon 2022 bp. The resulting plasmid was designated
pCR4-LAEO-CpC-Gus or JL111. To build the integration plasmid with His-tagged cassettes, JL111
was digested with NotI and self ligated to remove the pCR4 scaffold. The ligation was then used as a
template with the primers pGK-cpc-F and CpNoCtsR-R or pGK-cpc-R. If CpNoCtsR-R was used,
the CtsR repressor was removed along with GusA from the integration vector and an amplicon of
7,192 bp was expected. Conversely if pGK-CpC-R was used, CtsR remained intact and GusA was
removed and a band 7,824 bp was amplified. GusA-His and GFP-His were amplified using pET30
Gus or GFP plasmids with Pet-NdeF and pET-His-tag-R. The GusA-His and GFP-His were then
separately stitched into the integration vector using DIC. The reaction was then transformed into
E. coli (EC101). Transformants were screened using colony fluorescence and diagnostic digests
with GFP-His. pInt-Gus was verified using colony PCR, using the primers pET-Nde-F and Aterm-
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Figure 8: Construction of the three helper plasmids. Numbers above the primer refer to the primer table
(Table 2).
DicR with positive colonies having an amplicon of 2013 bp. Positive colonies were then verified by
restriction digests of the plasmid preps (Figure 11).
4.2 Integration Plasmid System Results and Discussion
4.2.1 Helper Plasmid Construction
As stated previously, pGK12 contains two antibiotic resistance markers to erythromycin and chlo-
ramphenicol. The helper plasmid was designed to include the chloramphenicol marker with the
erythromycin resistance marker deleted. During our preliminary work it was discovered that E. coli
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loses pGK derivative plasmids quickly when there is no antibiotic selection. To determine plasmid
stability we cloned LacZ into the ErmC locus under the control of the E. coli LacP. We found that
at 37, approximately 50% of the colonies showed signs of colony sectoring when plated on a LB-
X-gal/IPTG plate without antibiotic selection. Furthermore, when the temperature was increased
to 42 nearly all the colonies were white, indicating the plasmid was lost, after being plated on
a LB- X-gal/IPTG plate (data not shown). Three plasmids that could serve the function of the
helper plasmid were built: a plasmid with LacIPZ the same orientation as the erythromycin pro-
moter (pGK-∆Erm-LacZsense or JL101), a second with LacIPZ in the opposite orientation as the
erythromycin promoter (pGK-∆Erm-LacZantisense or JL102), and a third where the erythromycin
ORF was removed and the ends of the plasmid were ligated together (pGK-∆Erm or JL103) (see
Figure 8).
We were able to construct all three versions of the helper plasmid (Figure 8). We chose to
use the pGK ∆ Erm lacZsense plasmid as our helper plasmid because it offers more methods of
detection while in E. coli (via blue/white screening). Furthermore, the LacZ cassette provides more
primer binding sites to be used during future verification processes.
4.2.2 Construction of the Integration Plasmid
Construction of the integration plasmid provided us with some interesting challenges: 1) propagat-
ing a plasmid without a functional origin of replication, 2) the final integrated product had to be
food grade, and 3) the plasmid must contain the site for integration into the L. reuteri genome.
To deal with the propagation issue we decided to build the integration plasmid using the pCR4
vector (Invitrogen) as a scaffold. The blunt end sequencing version of the plasmid was chosen to
host the components of our integration plasmid. This version of pCR4 was chosen because of the
paucity in restriction sites within the plasmid (Figure 9). Fewer restriction sites allowed the system
to maintain high versatility. If the plasmid contained too many restriction sites, future integration
sequences might be limited because they contain restriction sites found within the multiple cloning
site (MCS) of the pCR4 plasmid. When construction of the integration plasmid started, we planned
on using the SlpA expression system to drive peptidase expression. Therefore, constructs were built
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Figure 9: MCS and vector map of pCR4 sequencing plasmid. Note the locations of the native SpeI, PstI
and NotI restriction sites. Figure adapted from Invitrogen website, http://www.invitrogen.com
using PLST (from Slp-A) as inserts to blunt end clone into pCR4 [65]. PLST was used as a place
holder in the TOPO Cloning site while the remaining parts of the integration vector were inserted
into pCR4.
The original plan was to use the SpeI and PmeI sites to hold our screenable marker, the origin
of replication, and the site of integration (see diagram of pCR4 vector). The fragment ligated into
the SpeI site would have a NotI site located at its 5’ end downstream the SpeI site. The pCR4
plasmid contains a native NotI site downstream of the DNA sequences we will insert. Using these
two NotI sites (native and engineered) we can cut away the pCR4 backbone and self ligate the
integration plasmid together. This system allows us to build an integration vector in the context
of a high copy number plasmid and then isolate the integration vector once it is constructed.
As stated in the expression vector section above, the CpC-GusA cassette was inserted into the
pCR4 scaffold vector using EcoRI sites. Furthermore, the GFP or GusA cassettes possess a His-tag
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acquired from pET30 MCS. Built into the pET30 MCS is an additional NotI cut site before the
His-tag coding sequence. This additional NotI site is incompatible with our plan to excise our
suicide vector from PCR4, as it would result in the loss of the terminator region of our expression
cassette. To solve the problem, we delayed inserting our His-tagged marker until the final stage
and used a digestion independent cling step to complete the construction (see details in methods
section and/or Figure 10).
4.2.3 Propagation of Integration Plasmids
The integration plasmids must have an external source of the RepA protein to replicate. We found
the helper plasmid was unable to provide adequate levels of RepA in E. coli to propagate both
plasmids. To solve this issue, we obtained a RepA expressing strain of E. coli (EC101) which has
been used in the construction of a similar integration vector [42]. Using this strain we were able to
successfully construct and propagate the integration plasmid. To confirm the construction of the
integration cassettes (GFP or GusA), diagnostic digests were used. Both plasmids were digested
using HpaI and XhoI (Figure 11). HpaI cuts near the 3’-end of the ErmC ORF, while XhoI cuts
within at the 3’-end expression cassette and is introduced via the pET30 vector. The expected
digest products for pInt-Clp-Gfp with HpaI and XhoI are 2,669 bp and 1,398 bp. The digest
of pInt-Clp-GFP shows 2 bands at approximately 1.4 kb and 2.6 kb (Figure 11). The expected
digest products for pInt-Clp-Gus with HpaI and XhoI are 3,765 bp and 1,398 bp, which were also
observed. Therefore, these digests confirm both pInt-Clp-Gus and pInt-Clp-GFP are built correctly
and contain the expression cassette from pET30 and the ErmC ORF.
To prepare L. reuteri for gene integration the pGK ∆ Erm lacZsense helper plasmid was trans-
formed into L. reuteri 10-23C. After inserting the helper plasmid, we successfully transformed
pInt-clp-GFP into L. reuteri, with ∆ Erm lacZsense providing RepA. A slight increase in GFP fluo-
rescence was observed in L. reuteri containing pInt-clp-GFP (data not shown). The CtsR repressor
protein has been found in many Gram positive bacteria including Lactobacillus [19]. L. reuteri may
be expressing CtsR from its genome reducing the activity of the clp promoter in the integration
plasmid. At this time, we have not verified genomic integration of the plasmid into the LacA gene.
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However, we do have a strain of L. reuteri which exhibits a continued resistance to erythromycin
and sensitivity to chloramphenicol (data not shown). We are continuing our investigations to verify
and increase the integration events.
A greater proportion of the EC101 with JL120 (int-Clp-GFP) cells fluoresce than do the dH5α
cells with JL115(pGk-Clp-GFP) (compare glowing cells between Figure 12 and Figure 6). As stated
previously, the pGK plasmid is not stable within E. coli ; therefore, it is expected that the population
of cells may contain a subset of cells that have lost the pGK plasmid derivative. EC101 expresses
RepA from its genome which may increase the stability of plasmids with the pGK origin based
upon expression levels. An increased stability of the pGK derivatives in EC101 would explain the
greater proportion of GFP positive cells, than pGK derivatives in other E. coli strains. Individually
cells harboring pInt-Clp-GFP(JL120)(E. coli EC101) fluoresced less brightly than cells harboring
to pGK-clp-GFP(JL115)(dH5α). The different levels of expression could be due to the background
strain of E. coli (dH5α vs EC101).
The pInt-clp-gus plasmid(JL119) shows increased GusA activity compared to bacteria without
the plasmid (Figure 13). In fact, the EC101 harboring JL119 has ∼590X more GusA activity as
EC101 alone. However, pGK-clp-Gus (JL116) has ∼4X the activity as seen with JL119 in EC101
(compare Figure 13 and Figure 5). The differences in enzymatic units produced may be due to
differences in the plasmid copy number allowed by each strain. Another possibility is that dH5α
may have higher levels of transcription and/or translation than EC101.
5 Cre Expression Vector
For our antibiotic marker in the integration vector we chose to use the ErmC gene from pGK12.
However if we wanted our probiotic to be food grade, we recognized the fact that our end product
cannot harbor resistance to erythromycin [18]. Therefore we developed a system that allowed us
to use the antibiotic resistance as a selectable maker during the construction of our bacteria and
remove the antibiotic resistance after the plasmid integrated into the genome. To accomplish this,
the Cre/Lox system was used. Cre is an integrase protein that is found in the coliphage P1 [13].
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Figure 10: Construction of the integration plasmid. The numbers above the primers refer to Table 2. To
build the integration plasmid with GFP, use the same primers and methods, however use pET30 GFP to
combine with the integration vector backbone instead of JL114.
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Figure 11: Verification of integration plasmid construction via enzymatic digestion. Enzymes used are in
parentheses. Expected band sizes for pInt-clp-GFP are 2669 bp and 1398 bp, pInt-clp-Gus are 3765 bp and
1398 bp.
Figure 12: Verification of pInt-Clp-GFP (JL120) activity. The plasmid is harbored within EC101. The
exposure time is in seconds and is reported in the lower right corner.
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Figure 13: Verification of pInt-Clp-GusA (JL119) activity. The plasmid is harbored within EC101.
Enzymatic units are defined as µM pNP−/min.
Cre recognizes two 34 bp site (LoxP) and catalyzes the recombination and removal of the contents
between the LoxP sites. This system provides an opportunity to utilize the convenience of antibiotic
selection, as well as ultimately producing a food grade product. Lox sites were added using the
primers created to amplify the ErmC antibiotic marker and origin of replication from pGK12. With
standard LoxP sites, an active LoxP site still exists within the genome after the recombination event
occurs. In order to eliminate this factor, modified LoxP sites were used [41]. By modifying 5 nt
on the 5’ end of one LoxP (creating Lox66) site and the 3’ end of the other LoxP site (creating
Lox71), the LoxP site is inactivated (designated Lox72) after the recombination by the Cre enzyme.
The modification of the Lox site is considered to be an important step as it eliminates a possible
genomic recombination hot spot in the genome of L. reuteri. After the Lox sites we also engineered
PstI sites on the ends of the ErmC-Origin amplicon. These cut sites allowed for the insertion of
the antibiotic marker and RepA dependent origin into the of the pCR4 plasmid.
For this study we needed an expression system for Cre recombinase that would propagate itself
in L. reuteri.bUsing pGK12 as a backbone ensured the system would propagate itself in L. reuteri.
It was also important that the expression of the Cre protein was inducible. Other studies have used
a nisin inducible system to induce control the expression of Cre [13]. The nisin inducible system
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was not used for this study because it requires the nisin operon to be included into the plasmid
system. Instead, the inducible ErmC regulatory region was chosen to control the expression of the
Cre ORF. With our system cells that have undergone a genomic integration will be resistant to
erythromycin. Therefore the CAT gene was required to select for the cre plasmid. Therefore, the
ErmC promoter was chosen to control Cre expression to maintain an unaltered chloramphenicol
resistance marker. The helper plasmid also contains the CAT gene, however it will have been cured
from cells that contain genomic integrants before transforming in the Cre plasmid. Therefore, these
two plasmids resistance markers will not interfere with one another because they will not be in the
same cell.
5.1 Methods for Cre Expression Vector
5.1.1 Building Cre Expression Plasmid
The Cre gene was obtained from the plasmid pMB145 (lab stock). The gene was amplified using
Erm5’Dic Cre-F and Cre-R with an expected amplicon of 1056 bp. The plasmid backbone was
amplified from pGK12 with pGK5’Erm-R and ErmDel-F2 yielding a band of 3908 bp. The two
amplicons were then gel purified with the Zymo Gel Pure Kit(Zymo Research) and digested with
EcoRI. The digests were ligated together to attach the 3’ end of the Cre cassette to the plasmid
backbone. The ligation was column cleaned using the Zymo Cleaner Concentrator Kit. DIC was
used to stitch the 5’ end of the Cre gene to the plasmid backbone. The annealing step of the Cre
DIC reaction was 40 due to a small stretch of homology. The plasmid was then transformed into
E. coli TURBO. Colony PCR was used to verify the construction of pGK5’Erm-Cre (JL1212) with
Cre-R and Lox-Ori-F2 to generate a 2.4 kb amplicon for positive colonies. (See Figure 14)
5.1.2 Activity Check of pGK5’Erm-Cre
The pGK 5’Erm-Cre plasmid was transformed into E.coli (dH5α T1R). The pUG6 plasmid [28]
was transformed into the dH5α containing pGK5’Erm-Cre(JLE121) cells and selected for using
both erythromycin and ampicillin(100 µg/ml). Colonies were picked and grown in liquid broths.
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Plasmids were obtained using the ZymoResearch Plasmid Prep Kit and screened by diagnostic
digests for positive transformants. To isolate pUG6 from pGK5’Erm-Cre, cells were plated on
LB-agar plates with ampicillin and grown at 42 for four successive generations. Plasmids were
digested with NdeI, SacI, XhoI, and/or HindIII and DNA banding patterns were analyzed using
agarose gel electrophoresis to confirm Cre activity (Figure 15).
5.2 Results and Discussion of Inducible Cre Shuttle Vector
Early attempts to build the Cre expression plasmid involved ligating the Cre ORF into pGK12
under the control of the ErmC promoter. However, no successfully transformed cells were obtained
after multiple attempts. It was suspected that the Cre cassette was being expressed from the ErmC
locus at levels high enough to be toxic to the cells, as the expression of Cre has been reported as
toxic to E. coli [47]. Ma¨ho¨nen et al. (2004) engineered an intron into the Cre ORF thus making
the Cre enzyme inactive in bacteria. When expressed in eukaryotic cells, the intron was removed
and Cre was active. This option was not available for this study as our product was not intended
to be expressed in a eukaryotic background.
In an attempt to further reduce expression from the ErmC promoter, the mechanism of control
was further investigated.The regulation of gene expression in ErmC is at the translational level.
The mRNA of the ErmC contains two Shine-Dalgarno (SD) sequences that are separated by a
19 amino acid leader sequence [48]. When the ErmC gene is transcribed, the mRNA secondary
structure forms a hairpin that leaves the first SD sequence open; however, the secondary SD (which
starts translation of the methylase) sequence is inactivated by the mRNA secondary structure.
Upon exposure to low levels of erythromycin, erythromycin bound ribosomes stalls translation on
the leader peptide. The ribosomal stalling results in a change in mRNA secondary structure and
exposes the second SD sequence. Ribosomes not bound to erythromycin then bind to the second
SD sequence and translate the methyltransferase [9]. The mRNA secondary structure that creates
the inducible properties of the ErmC gene requires the 5’ region of the ErmC gene. It is possible
our original construct disrupted the secondary structure of the mRNA so the inducible properties
of ErmC were disrupted. Other groups have constructed fusion proteins with the ErmC gene and
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Figure 14: Construction of pGK-5’ErmCre. Numbers above primers refer to Table 2. pMB145 is a lab
stock provided by M. Black
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maintained the native regulation [9],[48], [11], [20]. To ensure the Cre cassette did not interfere with
the regulation of the ErmC gene, we inserted the Cre ORF after the 73rd amino acid encoded by
ErmC [20]. The fusion protein enabled the successful creation of a plasmid bearing the Cre coding
cassette (Figure 14). The plasmid construction was confirmed by digesting it with NdeI and SacI.
The digest should yield a banding pattern of 3560 bp and 1379 bp. The digestion of pGK-5’ErmCre
with NdeI and SacI yielded three bands approximately 4.8, 3.6, and 1.3 kb in size (Figure 15). The
largest is DNA fragment is assumed to be undigested pGK-5’ErmCre plasmid based on size and
intensity. The smaller two fragments are close to the expected band sizes of pGK-5’ErmCre and
indicate the plasmid is properly built.
To assess if functional Cre recombinase was produced from this plasmid, the plasmid was co-
transformed with the pUG6 plasmid [28]. The pUG6 plasmid (Figure 15 middle lane) contains two
antibiotic resistance markers, ampicillin and kanamycin. The kanamycin marker is flanked by LoxP
sites which are the target of Cre recombinase. By co-transforming pUG6 with our pGK-5’ErmCre
plasmid, we were able to determine if Cre was active via screens for the loss of kanamycin resistance
followed by diagnostic digest verification. If active Cre recombinase was expressed from pGK 5’Erm-
Cre the Cre enzyme would interact with pUG6 and recombine pUG6 and remove the kanamycin
resistance marker. It was found that the kanamycin resistance marker was rapidly removed from
pUG6 even before induction of Cre expression with erythromycin (Figure 15 far left lane). The
pUG6 plasmid was isolated from Kan sensitive strains and digested with HindIII and XhoI. The
digest of the parental pUG6 with these enzymes theoretically yields three bands 2484 bp, 1009 bp,
and 516 bp. If the kan marker is removed from pUG6, a the plasmid is linearized (2502 bp) when
digested with HindIII and XhoI. The digest of pUG6 before cotransformation with pGK-5’Erm-Cre
revealed three bands of approximately 2.5 kb, 1 kb, and 0.5 kb(Figure 15, second to last lane). After
cotransforming pUG6 with pGK-5’Erm-Cre digests with HindIII and XhoI reveal a single band at
∼2.5 kb (Figure 15 last lane). The loss of the kanamycin marker (1 and 0.5 kb bands) from the
digest suggest the Cre recombinase expressed from pGK-5’Erm-Cre is functional in E. coli.
These data confirm suspicions that the ErmC expresses its transcripts at a low level regardless
of erythromycin’s presence. Another possible explanation is that the chloramphenicol (another
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Figure 15: Construction and activity of pGK-5’ErmCre. Enzymes used to digest the plasmids are in
parentheses. The pGK-ErmCre digest produced two bands with expected sizes of 1379 bp. and 3560 bp.
The pUG6 linearized gives an expected band of 4009 bp. The pUG6 w/ kan digest has expected band sizes
of 516 bp, 1009 bp, and 2484 bp. The pUG6 w/o kan should yield a single band of 2502 bp.
translational inhibitor) has some cross-induction of the ErmC locus. The cross induction is unlikely
to express high levels of ErmC-controlled genes at high levels based upon previous studies that have
used chloramphenicol as their negative control when examining ErmC induction [9].
6 Summary of Work
The end goal of the project is to create a probiotic strain of L. reuteri that will act as a persistent
treatment for CD. The current treatment for CD is a life long gluten free diet, which is difficult to
accomplish with western diets. This project aimed to create a system to efficiently integrate genes
into the L. reuteri genome. The work contained in this thesis has generated a body of necessary
tools to integrate useful genes, such as a prolyl endopeptidase, into the L. reuteri genome and
maintain food grade status.
Previous researchers have used a similar dual plasmid system to drive genomic integration into
LAB [60]. However, the papers did not mention the need for a strain of E. coli that expresses RepA
from its genome. As a result, early investigations attempted to use the helper plasmids generated
to propagate the integration plasmids in E. coli. To alleviate the possible plasmid incompatibility
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encountered, from using pGK12 plasmid derivatives, RepA was expressed from plasmids with the
ColE1 origin of replication (pCR2.1 and pCR4). Multiple attempts to transform the integration
plasmids into strains of E. coli containing the non-pGK helper plasmids failed. It is possible ColE1
plasmids were not expressing RepA a high enough levels to properly support replication of the
integration plasmids. It is also possible cells containing a plasmid with the ColE1 origin do not
efficiently take up pGK derivative plasmids. To successfully propagate the integration plasmids we
requested a strain of E.coli (EC101) from a research group in the Netherlands [42]. The Kok lab
quickly responded and generously agreed to send us the strain of E. coli. After two months nothing
had arrived and I contacted the grad student who sent me the strain. After some investigation we
learned the grad student had promptly sent the strain, but upon arrival to the Los Angels U.S.
Customs Office the stain was destroyed. The Kok lab generously sent the strain again through
another carrier, and we received the E. coli strain and we were able to propagate the integration
plasmids.
Another problem that plagued this project was the transformation of L. reuteri. Researchers
have been able to transform L. reuteri with high efficiency [3], however in our hands we have had
extremely low transformation efficiencies. A potential problem is the autoclaves in at our facilities
seemed to caramelize the media we used to grow the bacteria. The caramelization of the media is
thought to greatly decrease the transformation efficiency in L. reuteri (personal communications
with Matt Shurtluff). The problem was eventually solved by reducing the temperature of the
autoclave below 121 typically used to sterilize liquids and changing the media from MRS(Oxid)
to LCM [3].
Initial plans to build the pGK-Cre expression vector involved using a simple replacement of the
ErmC ORF with the Cre ORF. However, multiple attempts to ligate Cre into the pGK-∆-Erm
backbone failed. When the ErmC ORF was removed from the plasmid the inducible properties or
the ErmC promoters were disrupted. Therefore, the ErmC promoter constitutively expressed the
Cre enzyme. The high levels of Cre may have been toxic to E. coli [47] and prevented successful
transformation. Only by creating a Cre fusion protein with the 5’ end of the ErmC ORF could the
pGk-Cre shuttle vector be created.
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Though the project was full of unforeseen complications an integration system was developed
which will be instrumental in creating a probiotic strain of bacteria to treat CD. This thesis has
developed a plasmid based system to integrate genes into L. reuteri. Furthermore, the system
has the ability to utilize the convenience of antibiotic selection during the gene integration process,
then remove the resistance marker via Cre recombinase. With the antibiotic resistance removed, the
probiotic bacteria is more suitable as a food grade product. The integration system also maintains
a high degree of plasticity because the integration site can be changed via by removing the LacA
site and ligating in a new target sequence. Also, the gene to be to be integrated to can be changed
by cutting out the current gene(GusA or GFP) with AscI and ligating in a new gene. Though
originally developed for uses in L. reuteri this plasmid system can be utilized to integrate genes
into any bacterial species able to host plasmids with the pGK origin of replication. As a result,
this system may be use to create other probiotic bacteria which could host enzymes such as lactase
or α-galactosidase. The proteins responsible for generating immunity could be integrated into the
bacterial genome and the bacteria could be used as a delivery mechanism for vaccines development.
7 Future directions
After confirming successful integration of our reporter genes, the integration plasmid should be re-
examined to find a better integration site within the L. reuteri genome. It is possible interrupting
LacA will result in a competitive disadvantage for the bacteria when colonizing the duodenum.
If a competitive disadvantage is observed a different integration site should be used to ensure the
bacteria can successfully colonize the intestine. Furthermore, a prolyl endopeptidase must be chosen
to replace our reporter genes (GFP and GusA). Within our lab, we are currently working with
a number of peptidases to determine which enzyme most effectively digests the gluten fragments
known to trigger CD. This peptidase must also contain a leader sequence to direct it to the bacterial
cell surface and an anchor sequence to keep the peptidase from being excreted into the intestinal
lumen. Once these hurdles are overcome, the dairy department at Cal Poly should be consulted on
how to best deliver the probiotic bacteria to consumers. They have extensive experience in working
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with food grade microbes and likely will provide key insights for our probiotic delivery techniques.
Once a delivery system for our probiotic is developed the probiotic should begin small scale tests
to ensure safety and effectiveness of the probiotic to alleviate CD symptomologies.
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